Chemical Name : Eltrombopag/
CAS : 496775-61-2
Synonyms: 3-(5-[2-[2-(3,4-DIMETHYLPHENYL)-5-METHYL-3-OXO-2,3-DIHYDRO-1H-PYRAZOL-4-YL]HYDRAZIN-1-YLIDENE]-6-OXOCYCLOHEXA-1,3-DIEN-1-YL)BENZOIC ACID
Storage:-20
Biologieal
Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals
Reference
GlaxoSmithKline (2008-11-20). "FDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder". Press release. http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10127.htm. Retrieved 2008-11-25. ^ Jenkins JM, Williams D, Deng Y, et al. (2007). "Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist". Blood 109 (11): 4739�C41. doi:10.1182/blood-2006-11-057968. PMID 17327409. http://bloodjournal.hematologylibrary.org/cgi/content/full/109/11/4739.